Clinical and histological impact of omalizumab in oral corticosteroid-dependent severe allergic asthma

C. Domingo Ribas (Sabadell, Spain), F. González-Barcala (Santiago de Compostela, Spain), F. Garcia (Barcelona, Spain), D. Moriña (Barcelona, Spain), F. Salgado (santiago de Compostela, Spain), V. Marco (Barcelona, Spain), J. Oliva (Sabadell, Spain), R. Mirapeix (Sabadell, Spain)

Source: International Congress 2019 – Novel findings from asthma clinical trials
Session: Novel findings from asthma clinical trials
Session type: Oral Presentation
Number: 5335

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Domingo Ribas (Sabadell, Spain), F. González-Barcala (Santiago de Compostela, Spain), F. Garcia (Barcelona, Spain), D. Moriña (Barcelona, Spain), F. Salgado (santiago de Compostela, Spain), V. Marco (Barcelona, Spain), J. Oliva (Sabadell, Spain), R. Mirapeix (Sabadell, Spain). Clinical and histological impact of omalizumab in oral corticosteroid-dependent severe allergic asthma. 5335

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: